My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece
   Program
   Organisers
   Abstracts
   Participants

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland

Printable version

 

Tuesday June 7

 

08.00-19.00 Registration at Hotel Divani Caravel
       
19.00-21.00 Opening Ceremony at the Hotel Divani Caravel (Olympia hall), continued with cocktails at the hotel’s roof garden by the pool 
       

 

Wednesday June 8

 

07:00-08:45 Registration
       
08:45-09:00 Welcome and Introduction
       
09:00-10:00 PKPD-modelling in Multiple Sclerosis and Infection

chair: Panos Macheras and Aris Dokoumetzidis 

09:00-09:20 Pascal Girard    A Semi-mechanistic Model of Lymphocyte Dynamics in Patients with Multiple Sclerosis Treated with Cladribine Tablets  
09:20-09:40 Mats Karlsson Population Pharmacodynamics of Cladribine Tablets Therapy in Patients with Multiple Sclerosis: Relationship between Magnetic Resonance Imaging and Clinical Outcomes
09:40-10:00 Bambang Adiwijaya An integrated, mechanistic model of viral eradication and its clinical applications in treatment regimens with direct-acting antivirals for chronic hepatitis C
       
10:00-10:15 Lutz Harnisch and Mats Karlsson Presentation of DDMoRe
       
10:15-11:45 Coffee break, Poster (Ilissos) and Software (Olympia foyer) session I
  Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter
       
11:45-12:30 Time to event Tutorial (I) chair: France Mentré
11:45-12:45 Nick Holford and Marc Lavielle A tutorial on time to event analysis for mixed effect modellers
       
12:45-14:15 Lunch: Macedonia hall
       
14:15-14:55 Oral session chair: France Mentré
14:15-14:35 Chuanpu Hu Informative Dropout and Visual Predictive Check of Exposure-Response Modeling of Ordered Categorical Data
14:35-14:55 Chee Ng Novel GPU-based Parallelized Qausi-random Parametric Expectation-Maximization (QRPEM) Estimation Method for Population Data Analysis  
       
14:55-16:10 Tea break, Poster (Ilissos) and Software (Olympia foyer) session II
  Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter
       
16:10-17:30 Stuart Beal Methodology Session: Modelling strategies chair: Lutz Harnisch
16:10-16:30 Patanjali Ravva Covariate Modelling in Aggregate Data Meta Analysis: A Simulation Study Evaluating Performance of Model Linearization  
16:30-16:50 Marc Gastonguay Full Covariate Models as an Alternative to Methods Relying on Statistical Significance for Inferences about Covariate Effects: A Review of Methodology and 42 Case Studies.
16:50-17:10 Céline Laffont How to analyse multiple ordinal scores in a clinical trial? Multivariate vs. univariate analysis.
17:10-17:30 Julie Bertrand Some Alternatives to Likelihood ratio and Wald Tests for Pharmacogenetic studies using nonlinear mixed effect models.
       
 

 

Thursday June 9

 

08:30-09:50 Lewis Sheiner Student Session

chairs: An Vermeulen, Alison Thomson, Niclas Jonsson, Malcolm Rowland 

08:30-08:55 Abhishek Gulati Linking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity
08:55-09:20 Joshua Pink Pharmacokinetic-pharmacodynamic-pharmacoeconomic analysis of rituximab for follicular lymphoma
09:20-09:45 Elodie Plan Modelling Techniques Handling Dynamic Pain Scores Characteristics
09:45-09:50 Presentation of Awards  
       
09:50-11:05 Coffee break, Poster (Ilissos) and Software (Olympia foyer) session III
  Posters in Group III (with poster numbers starting with III-) are accompanied by their presenter
   
11:05-12:15 PBPK chair: Marylore Chenel
11:05-11:55 Malcolm Rowland Physiologically based pharmacokinetics: Advancing the clinical dimension
11:55-12:15 Ashley Strougo Scaling pharmacokinetics to estimate the “first dose in children”: comparing allometric scaling and PBPK
       
12:15-13:45 Lunch: Macedonia hall
       
13:45-15:05 PKPD-modelling of tumour effects and adverse events for anticancer drugs chair: Dinesh De Alwis
13:45-14:05 Benjamin Ribba Evaluation of the antitumor effect of PCV chemotherapy on low-grade gliomas patients with a longitudinal tumor growth inhibition model
14:05-14:25 Emma Hansson PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3 and sKIT as Biomarkers of Tumor Response and Overall Survival Following Sunitinib Treatment in GIST
14:25-14:45 Inès Paule Individual Prediction-Based Dose Adaptation Of Capecitabine: In Silico Comparison With The Standard Method, Impact On Limiting Toxicity and On Antitimour Efficacy
14:45-15:05 Coen van Hasselt Optimizing monitoring strategies of trastuzumab induced cardiotoxicity: Development and application of a population pharmacodynamic model quantifying trastuzumab induced changes in cardiac function
       
15:05-16:20 Tea break, Poster (Ilissos) and Software (Olympia foyer) session IV
  Posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter
       
16:20-17:20 Design chair: Steve Duffull
16:20-16:40 Lee Kien Foo Cost minimization of a phase IIA clinical study
16:40-17:00 Sebastian Ueckert Explicit Optimization of Clinical Trials for Statistical Power
17:00-17:20 Peter Gennemark Optimal design in population kinetic experiments by set-valued methods
       
20:00-01:00 Social evening
   
 

 

Friday June 10

 

09:00-10:20 Target-mediated drug disposition chair: Charlotte Kloft
09:00-09:40 Leonid Gibiansky Modeling of Drugs with Target-Mediated Disposition
09:40-10:00 Stefaan Rossenu Population Pharmacokinetic/Pharmacodynamic Modeling of a New Antithrombotic Drug, The Nanobody® ALX-0081
10:00-10:20 Angelica Quartino An integrated G-CSF-myelosuppression model characterizing the target mediated disposition of endogenous G-CSF in breast cancer patients following chemotherapy
       
10:20-10:30 Preview of PAGE 2012
       
10:30-10:40 Preview of WCoP 2012
       
10:40-11:10 Coffee Break
       
11:10-12:30 Modelling and methods for complex systems chair: Oscar Della Pasqua
11:10-11:30 Stephan Schmidt Coping with Time Scales in Disease Systems Analysis: Application to Bone Remodelling
11:30-11:50 Elba Romero Coupling complex mechanistic PK/PD modelling with dynamic system analysis to obtain relevant clinical/biological insights. Application to gonadotropin hormone release agonist
11:50-12:10 Wojciech Krzyzanski Solving Delay Differential Equations in S-ADAPT by Method of Steps
12:10-12:30 S. Y. Amy Cheung   Structural identifiability of parallel pharmacokinetic experiments as constrained systems
       
12:30-12:40 Closing Remarks
       
12:40-12:55 Audience Input for the PAGE 2012 Program

 

Software demonstrations: Olympia foyer (Level -1)

Kajsa Harling Perl speaks NONMEM (PsN) and Xpose
Marc Lavielle Analysing population PK/PD data with MONOLIX 4.0
Joakim Nyberg PopED - An optimal experimental design software
Coen van Hasselt Piraña: The flexible modeling environment for NONMEM
Stephane Vellay Pipeline Pilot - Data Integration, Analysis, and Reporting Platform

Posters: Absorption and physiology-based PK

I-10 Christian Bartels Population PK Model for Pooled Data of Different Oral Diclofenac Formulations
I-35 Vicente G. Casabo Bioequivalence trials simulation to select the best analyte for acetylsalicylic acid
I-62 Kristin Dickschen Pharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites
II-20 Ludivine Fronton Monoclonal Antibody Disposition beyond Target Binding: Impact of FcRn on Clearance and Derivation of Mechanistic Compartment Models
II-40 Emilie Hénin Meta-analysis of Magnetic Marker Monitoring data to characterize tablet movement through the gastrointestinal tract
III-9 Donghwan Lee Development of a population model to describe diurnal and chronokinetic variation in cilostazol pharmacokinetics
III-26 Eugeniy Metelkin A Systems Pharmacology Model of Anandamide Dynamics After FAAH Inhibitor Administration
III-35 Christoph Niederalt Development of a detailed physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats
III-40 Kayode Ogungbenro A semi-mechanistic gastric emptying pharmacokinetic model for 13C-octanoic acid: an evaluation using simulation
III-54 Anna Pieper Development of a PBPK model of doxorubicin
IV-8 Alexander Solms Modelling Inter-Individual Variability in PBPK Models and Deriving Mechanistic Covariate Models for PopPK
IV-21 Sonya Tate The Importance of Enterohepatic Recirculation in the Disposition of Pravastatin and Rosuvastatin: A Physiologically-Based Pharmacokinetic Modelling Approach
IV-47 Thomas Wendl Development of a physiologically-based pharmacokinetic (PBPK) model for Moxifloxacin and its metabolites in healthy adults
IV-65 Kirill Zhudenkov Pharmacokinetics of PEG-IFN Alpha in HCV Infected Patients

Posters: Cardiovascular, QT-prolongation

I-14 Francesco Bellanti Relevance of QT-RR correlations in the assessment of QTc-interval prolongation in clinical trial simulations
I-28 Christine Brandquist PK/PD Modeling of the Effect of Intravenous Doses of Anzemet® (dolasetron mesylate) and Its Metabolite (hydrodolasetron) on the QT Interval in Healthy Subjects
I-37 Anne Chain Can First-Time-In-Human Trials Replace Thorough QT Studies?
I-63 Jeroen Diepstraten Pharmacodynamics of nadroparin using anti-Xa levels in morbidly obese patients upon subcutaneous administration of 5700 IU
II-1 Vincent Dubois Translation of drug-induced QTc prolongation in early drug development.
II-11 Farkad Ezzet Meta-Analysis of Antiplatelets in Patients with Atrial Fibrillation: A survival Model
II-44 Eleanor Howgate PKPD Modelling Of Cardiovascular Safety Pharmacology Data
II-55 Helene Karcher Probabilistic risk assessment for QT prolongation and heart rate increase
III-41 Oliver Ackaert  Population modelling of blood pressure: assessing clinically important factors for cardiovascular diseases
IV-6 Nelleke Snelder Quantitative understanding of drug effects on the interrelationship between mean arterial blood pressure, cardiac output and total peripheral resistance
IV-36 Piet van der Graaf Towards a Thorough Preclinical QT (“TpQT”) study paradigm: Pharmacokinetic-Pharmacodynamic (PKPD) Modelling of QTc Effects of Moxifloxacin in Cynomolgus Monkeys

Posters: CNS

I-22 Irina Bondareva Sequential Interacting Multiple Model (IMM) Bayesian Analysis of Carbamazepine and Valproate Repeated Therapeutic Drug Monitoring (TDM) Data from Epileptic Patients
I-32 Jacob Brogren Separate vs. simultaneous analysis of co-primary endpoints in Alzheimer’s disease clinical trials
I-56 Elizabeth de Lange Mechanism-based PK-PD model of remoxipride with rat-to-human extrapolation: characterizing remoxipride target site PK and systems homeostatic feedback
II-25 Martin Gnanamuthu Johnson Predicting Dopamine D2 Receptor Occupancy in humans using a physiology-based approach
II-26 Martin Gnanamuthu Johnson Pharmacokinetic-Pharmacodynamic Modeling of Dopamine D2 Receptor Occupancy in humans using Bayesian modeling tools
II-34 Zheng Guan Population pharmacokinetic and pharmacodynamic analysis of cortisol in serum and saliva in healthy male volunteers after an acute 5-hydroxytryptophan (5-HTP) challenge test
II-42 Eef Hoeben Population pharmacokinetic analysis of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia
II-48 Masoud Jamei A physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain
II-65 Huub Jan kleijn Development and Application of a Semi-Mechanistic Model for Modulation of Amyloid-beta in Cerebrospinal Fluid after Inhibition of γ-secretase.
III-16 Arianna Madrid Modelling the sleep effects of Zolpidem in rats using non-homogeneous Markov chain models
III-25 François Mercier A Bayesian meta-analysis of longitudinal lesion count data in multiple sclerosis patients
III-56 Venkatesh Pilla Reddy Exposure-Response Relationship of Typical and Atypical Antipsychotics Assessed by the Positive and Negative Syndrome Scale (PANSS) and its Subscales
III-58 Bart Ploeger Confirmation of symptomatic and disease modifying effects of levodopa using the ELLDOPA study
IV-15 Ahmed Suleiman A Mixed-Effects Markov Model for Characterizing the Time Course of the Transitions between Different Extrapyramidal Side Effects Severity Levels
IV-19 Stina Syvänen Quinidine Microdialysis Reveals Altered P-glycoprotein Function in Epileptic Rats in the Brain Parenchyma Rather than at the Blood-Brain Barrier
IV-30 Karin Tunblad A pharmacokinetic/pharmacodynamic analysis of central and peripheral effects of GSK3 inhibitors 

Posters: Endocrine

I-45 Steve Choy Application of an integrated glucose-insulin model to investigate the effects of glibenclamide and its active metabolites on postprandial glucose and insulin concentrations in healthy volunteers
II-7 Petra Ekerot Mechanism-based Pharmacokinetic-Pharmacodynamic Feedback Model of Thyroid Hormones after Inhibition of Thyroperoxidase in the Dog. Cross-species Prediction of Thyroid Hormone Profiles in Rats and Humans.
III-6 Anna Largajolli Meal Tolerance Test (MTT): Nonlinear Mixed-Effects Modeling of Insulin Secretion
III-29 Jonas Bech Møller Model-based Analysis of the GLP-1 Response following an Oral Glucose Tolerance Test (OGTT)
III-46 Joanna Peng A Mechanistic Model for the Effects of A Novel Drug on Glucose, Glucagon and Insulin Applied to Adaptive Phase II Design
III-49 Kirill Peskov A Quantitative Systems Pharmacology Model Provides Insights into Phosphate Homoeostasis through Multiple Interacting Pathways
IV-37 Piet van der Graaf Application of a Multiscale Physiologically-Based Bone and Calcium Systems Model to Guide the Development of GnRH receptor modulators for the Management of Endometriosis
IV-59 Stefan Zajic Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine and Distal Forearm Bone Mineral Density in Two Phase II Studies of Postmenopausal Women

Posters: Estimation methods

I-29 Karl Brendel A comparison of MONOLIX, NONMEM 6 and NONMEM 7 based on a simulated PK example
I-44 Jason Chittenden Evaluation of the Lindstrom-Bates FOCE Algorithm with Simulated Pharmacokinetic Datasets
I-50 Emmanuelle Comets SAEMIX, an R version of the SAEM algorithm
I-54 Alexander Danis Set-valued methods for estimation of parameters in population models
II-29 Helen Graham Development of a novel method for updating the predicted partition coefficient values generated by an existing in silico prediction method
III-8 Robert Leary Exact Reproducibility of Population PK/PD NLME Numerical Results across Different Computational Environments
III-42 Erik Olofsen Population Analysis of Kalman-Filtered Permutation Entropy of the Electroencephalogram
III-43 Itziar Oteo Differences among six prevalent creatinine clearance calculation methods by covariate modeling of CL for Netilmicin using NONMEM for inference
IV-41 Georgios Vlasakakis The impact of modified-release formulations on bridging of pharmacokinetic data from adults to children

Posters: Infection

I-2 Mona Alameddine Population Pharmacokinetic Analysis and Effects of Raltegravir In HIV positive and Healthy Individuals
I-3 Sarah Alghanem Development of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic Fibrosis
I-16 Julie Bertrand Extensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients
I-30 Margreke Brill Cefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery.
I-39 Georgia Charkoftaki Pharmacokinetics of doripenem in cerebrospinal fluid
I-46 Christine Xu Population Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV
I-60 Paolo Denti Population PK of Isoniazid in South African Adults.
II-17 Monika Frank Integrated Population Pharmacokinetic Model Development of Nevirapine for Mothers and Newborns including Healthy Male Volunteer Data
II-22 Maria Garrido Population Pharmacokinetics/Pharmacodynamics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in SOT Patients Infected with CMV
II-27 Sylvain Goutelle Comparison of Four Renal Function Estimator-Based Models for the Prediction of Gentamicin Concentrations in Geriatric Patients by Use of Nonparametric Population Approach
II-35 Monia Guidi Population Pharmacokinetics of Nevirapine in HIV-positive Patients
II-43 Richard Höglund Population modelling of the pharmacokinetics of a mefloquine-artesunate treatment at the Thai-Myanmar border
II-46 Arantxa Isla Population Pharmacokinetics of Cefoxitin as a Prophylactic Antimicrobial Agent
II-60 Dalia Khachman Optimising ciprofloxacin dosing in intensive care patients based on pharmacodynamic target attainment
II-61 David Khan PKPD-modeling of time-kill curves from E. coli mutants exposed to ciprofloxacin
III-5 Ryuji Kubota A Novel Framework of Long-term Prediction of integrase inhibitors for treatment naïve patients
III-36 Elisabet Nielsen PK/PD Indices of Antibiotics Predicted by Mechanism-Based PKPD Models
III-63 Dinko Rekic Bilirubin - a biomarker of atazanavir exposure in HIV/AIDS patients
IV-4 Andre Schäftlein Comparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models
IV-9 Ivy Song Applications of Population Pharmacokinetic Modeling during Phase2B to Support the Clinical Development of Dolutegravir (DTG, S/GSK1349572)
IV-12 Joe Standing Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents
IV-16 Elin Svensson Mega-model of nevirapine population pharmacokinetics
IV-17 Vinogradova Svetlana Applying of population PK-PD methods to analysis of viral dynamics of HIV/HCV-Coinfected Sustained Virological Responders and Nonresponders treated with PEG-IFN
IV-18 Ami Fazlin Syed Mohamed Pharmacokinetic-Pharmacodynamic Modelling of Pre-existing and Emerging Resistance of Pseudomonas aeruginosa to Colistin
IV-34 Marta Valle Effect of Ritonavir Concentrations on Atazanavir Pharmacokinetics: Population Pharmacokinetic Analysis
IV-35 Georgia Valsami Assessment of dosage regimens of tigecycline in hospitalised patients
IV-38 Jan-Stefan van der Walt The effect of nevirapine-based antiretroviral therapy on the population pharmacokinetics of artemether and dihydroartemesinin in HIV-infected adults
IV-42 Max von Kleist A Mathematical Modelling Framework to Assess the Impact of Nevirapine-based Prophylaxis on vertical HIV Transmission
IV-45 Toshihiro Wajima Pharmacokinetic/pharmacodynamic Modeling and Long-term Simulation of Dolutegravir (DTG, S/GSK1349572) in Integrase Resistant Patients with a Simple Viral Dynamic Model
IV-54 Hongmei Xu Mechanism-based Modelling of the Antagonism between Polymyxin B and Levofloxacin against Pseudomonas aeruginosa using Mono- and Combination Therapy
IV-57 James Yates Population PK/PD modelling of AZD9773 in patients with severe sepsis.
IV-62 Chao Zhang Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Adults
IV-66 Simbarashe Peter Zvada Population Pharmacokinetics of Isoniazid in Children with Pulmonary Tuberculosis

Posters: Inflammation

II-24 Leonid Gibiansky Mechanistic Modeling of the Link between Interleukin 6 Receptor Blockade with Tocilizumab and Its Hematological Effects
III-1 Gilbert Koch Semi-mechanistic modelling of collagen-induced arthritis in mice and of the effect of administration of an anti-Granulocyte Macrophage Colony-Stimulating Factor antibody using delay differential equations
III-55 Etienne Pigeolet Population PKPD modeling of dose-response and time course of peripheral lymphocytes after single and repeated administration of the S1P1/5 modulator, BAF312, in healthy volunteers.
IV-61 Miren Zamacona Model based approach to inform early clinical development for a biologic

Posters: Model evaluation

I-51 Emmanuelle Comets Prediction discrepancies (pd) for evaluation of models with data under limit of quantification
II-33 Namyi Gu Population Pharmacokinetics of a new TRPV1 antagonist in healthy volunteers.
II-49 Masoud Jamei Modelling the Effect of Interleukin-6, an Inflammatory Cytokine, on Time-dependent Reduction of Cyclosporine Clearance: An Application of the Simcyp Population-based Simulator to Suppression of CYP450 by Biologics
III-7 Marc Lavielle Improved diagnostic plots require improved statistical tools. Implementation in MONOLIX 4.0
III-10 Annabelle Lemenuel-Diot External evaluation of a Hepatitis C viral kinetic model which links viral dynamics to sustained virologic response (SVR)
III-51 Klas Petersson Assessment of bias in model parameter estimates of continuous time Markov models for categorical data

Posters: Oncology

I-6 Orna Amir Predictive Model for Identification of Responders/Non Responders in Metastatic Breast Cancer Patients Treated with Docetaxel
I-15 Brendan Bender A semi-mechanistic population Pharmacokinetic-Pharmacodynamic (PKPD) model of thrombocytopenia characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
I-21 Michael Block Mechanistic PBPK/PD modeling for prediction of study outcome of cancer therapies: Translating in-vitro information into valid in-vivo predictions
I-23 Guillaume BONNEFOIS A nonlinear mixed effect model to study albumin-mediated drug transport into endothelial cells in vitro.
I-24 Stephan Borghorst Age Dependent Volume of Distribution of Pegylated Asparaginase (OncasparTM) in children and adults
II-9 Fernandez Eric Using the Virtual Tumour to predict and optimize drug combination regimens
II-14 Gregory Ferl Population analysis of the DCE-MRI response of liver metastases to a single dose of bevacizumab in CRC patients
II-16 Nicolas Frances Integrating distribution to tumor tissue into a dynamic PK/PD model to evaluate the anti-cancer effect of erlotinib in patient-derived LXFA 677 tumor xenograft mice
II-28 Iztok Grabnar Bayesian Estimation of Methotrexate Pharmacokinetics in Children with Acute Lymphoblastic Leukaemia and Prediction of Folinic Acid Rescue
II-31 Joachim Grevel A physiology-based model predicts pharmacokinetics, target occupancy in the tumour, and HSP70 biomarker response in serum for the HSP90 inhibitor, 17-AAG
II-36 Neeraj Gupta Population PK and PK/PD Analysis of Intravenous Investigational Agent MLN9708 in Solid Tumors and Lymphoma Patients
II-52 Jin Jin Mechanism-Based Population Pharmacokinetic (PK) Modeling of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449), a Novel Molecule with Unique PK Nonlinearity in Humans
III-4 Steve Kuan Population Pharmacokinetic Modeling of Investigational Agent MLN4924 in Cancer Patients 
III-17 Paolo Magni A new population PK/PD model to assess the myelotoxicity of candidate drugs in preclinical and in clinical studies
III-21 Maria Matoses Osborne Ex Vivo modeling of the apoptotic effects of Vivia009 and its metabolite in patients with Chronic Lymphocytic Leukemia
III-30 Daniele Morpurgo Predicting the Gemcitabine efficacy by a stochastic language based model
III-34 Ronald Niebecker Importance of study design for estimation of Vmax and Km characterising nonlinear monoclonal antibody clearance
III-37 Valerie Nock Leukopenia following triple high-dose chemotherapy and stem cell rescue
III-50 Kirill Peskov Systems Modeling of EphB4/ephrinB2 Signaling Pathways
IV-3 Franziska Schädeli Stark A semi-mechanistic population pharmacokinetic model for trastuzumab emtansine (T-DM1) antibody-drug conjugate and total antibody in patients with metastatic breast cancer (mBC)
IV-11 Alexandre Sostelly Characterization of the interaction between irinotecan, SN-38 and MBLI-87, a new BCRP inhibitor, with a multi-scale semi-mechanistic PKPD model
IV-27 Mirjam Trame Busulfan Dosing in Children: Body Weight versus Body Surface Area or Allometric Body Weight Dosing
IV-50 Mélanie Wilbaux Population KPD modelling of CA125 and tumor size in patients with ovarian cancer
IV-58 James Yates Characterisation of Xenograft Response to Docetaxel by Nonlinear Mixed Effects Modelling
IV-63 Jianping Zhang Population Pharmacokinetics of Lapatinib in Cancer Patients

Posters: Other drugs and diseases

I-5 Claire Ambery Modelling impact of dropout mechanisms in Chronic Obstructive Pulmonary Disease (COPD)
I-9 Jacqueline Anderson Comparative pharmacokinetics of dimethoate poisoning in the minipig and human
I-49 Adriaan Cleton Population Pharmacokinetics of a Monoclonal Antibody Tanezumab in Chronic Pelvic Pain Conditions
II-23 Cecile Gerard Factors influencing pharmacokinetics of tacrolimus during the early liver post-transplantation period: a population analysis
III-2 Julia Korell Modelling red blood cell survival data
III-28 Dirk Jan Moes Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients on a calcineurin inhibitor free regimen
III-47 Mark Penney Using Mechanistic Modelling of Cyclic Neutropenia to Predict the Effects of a COPD Therapeutic on Systemic Neutrophil Levels
III-48 Henry Pertinez Physiologically based, POP-PK modelling of a bone seeking agent in the ovariectomised rat disease model of post menopausal osteoporosis.
IV-5 Rik Schoemaker Modelling Ordered Categorical Allergic Rhinitis Scores in an Environmental Exposure Unit Study
IV-40 Erno van Schaick PK-PD modelling of bone density and turnover effects of denosumab based on a circular model of bone remodelling
IV-51 Christian Woloch Population Pharmacokinetics of Mefloquine and its Major Metabolite in Healthy Volunteers.

Posters: Other topics - Applications

I-41 Marylore Chenel Developing an In Vitro – In Vivo Correlation Model Using a Population Approach in NONMEM
I-47 Jae Yong Chung Modelling of Atorvastatin Pharmacokinetics in relation to SLCO1B1 genotype and Simulations for Bioequivalence Study
I-57 Willem de Winter Dynamics of a Two-Receptor Binding Model: How Affinities and Capacities Translate into Long- and Short-Term Behaviour and Physiological Corollaries
I-59 Ivan Demin Longitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug development
I-61 Vincenzo Luca Di Iorio Application of Stochastic Differential Equations to Disease Progression in a Neuropathic Pain Model in Rats
II-2 Anne Dubois Pharmacokinetic bioequivalence analysis of biologics using nonlinear mixed effects modeling
II-3 Anne Dubois Clinical trial simulations to design a crossover study assessing the equivalence on the pharmacodynamic surrogate marker between an immediate and a modified release formulations
II-10 Charles Ernest Multinomial Markov-chain model of sleep architecture in Phase-Advanced Subjects (PAS)
II-15 Martin Fink Diversity: Academia-Industry Collaborations on Modeling and Simulation to enhance Scientific Capability Development – The Novartis Experience
II-21 Sathej Gopalakrishnan Population PK/PD evaluation of the effect of dienogest on Hoogland Score in young healthy women
II-37 Manish Gupta Application of Two-Target Quasi-Steady-State (QSS) Model in Population Pharmacokinetic and Pharmacodynamic (PK-PD) Modeling of MNRP1685A in Cynomolgus Monkeys
II-38 Serge Guzy Optimizing The Entire Drug Development Process Using Pharmacometric Tools: From Preclinical To Marketing
II-50 Candice Jamois Title Pharmacokinetic-Pharmacodynamic Modeling of the Relationship between Aleglitazar Exposure and Lipids Response in Type 2 Diabetes Patients.
II-51 Hyewon Jeon A Population Pharmacokinetic/pharmacodynamic Approache of Drug X in Healthy Korean
II-59 Thomas Kerbusch Phase 2b dose selection for the treatment of autoimmune disorders leveraging comparator data
III-13 Lay Ahyoung Lim Development of a longitudinal model for characterizing adverse events of psychiatric drugs in routine clinical care
III-22 Hugh McDevitt Technology Roadmap to Support Model Based Drug Development
III-27 Enrica Mezzalana Title: Quantitative Assessment of First Night Effect in a Polysomnographic Insomnia Study through a Multinomial Mixed-Effect Markov-Chain Model
III-31 Flora Musuamba-Tshinanu KPD modelling of trough FEV1 in chronic obstructive pulmonary disease (COPD).
III-44 Zinnia Parra Target Mediated Drug Disposition Model to Describe the Expression and Kinetics of IL12 And IFNγ in Gene Therapy
III-52 Olivier Petricoul From Animal to Human with a new monoclonal antibody: An example of the use of pharmacokinetics only to assist on the choice of first in human dose.
III-57 Gregory Pinault A structured approach to industrialize the data sourcing to support model based drug development
III-65 Martijn Ruppert Population PK/PD Modeling of a Hepatitis C NS3 Inhibitor
IV-2 Tarjinder Sahota Parameterisation of biomarker response in the assessment of long term safety
IV-7 Yi SoJeong Population Pharmacokinetics of a Novel Proton Pump Inhibitor, Drug Y, in Healthy Volunteers
IV-13 Andreas Steingoetter A population pharmacokinetic model for Gd-DTPA in DCE-MRI
IV-22 David Ternant Influence of the FcγRIIIa genetic polymorphism on the effect of antithymocyte globulins on lymphocyte populations in kidney transplantation
IV-26 Dorota Tomalik-Scharte Evaluation of Circadian Rhythms in Hepatic CYP3A4 Activity Using Population Pharmacokinetics of Midazolam
IV-32 Venkata Pavan Kumar Vajjah Application of pharmacometric principles to quantify the effect of decontamination on the pharmacokinetics, pharmacodynamics and event times of venlafaxine in overdose
IV-49 Pawel Wiczling Pharmacokinetics and Pharmacodynamics of Propofol in ASA III Patients Undergoing Abdominal Aortic Surgery
IV-52 Dan Wright Development of a Bayesian forecasting method for warfarin dose individualisation
IV-53 Rujia Xie Model based meta-analysis (MBMA) to support the development of decision criteria in dental pain studies
IV-55 Shuying Yang Predicting long term Placebo response based on short term observations:Meta-Analysis on FEV1 Response in Asthma Trials

Posters: Other topics - Methodology

I-11 Paul Baverel A novel covariate search method intended for PKPD models with nonparametric parameter distributions
I-13 Benoît Beck From the Experimental Model Settings to the Physical System for Interpretable Decision Making
I-17 Julie Bertrand Multiple SNP analysis with HyperLasso in Pharmacogenetic Studies using Nonlinear Mixed Effects Models
I-18 Bruno Bieth Using a Systems Biology Approach to Explore Clinical Diversity and Investigate Mechanism of Drug Action: Example of the RAAS System in Hypertension
I-19 Roberto Bizzotto Drug Effects on Sleep Data from a 28-Day Clinical Study in Insomniac Patients: Covariate Analysis Using a Multinomial Mixed-Effect Markov-Chain Model
I-20 Marcus Björnsson Performance of non-linear mixed effects models with and without taking informative dropout into account
I-25 Massoud Boroujerdi A Negative feedback model for a mechanism based description of longitudinal observations: application for bone turnover biomarkers.
I-26 Marion Bouillon-Pichault Modeling Pain score in clinical trials using a joint survival-longitudinal mixed model with a Beta distribution in presence of missing values not occurring at random.
I-31 Anne Brochot Specifying Models with Time Dependent Pharmacokinetic Parameters in NONMEM
I-33 Vincent Buchheit Efficient quality review for modeling input dataset
I-42 Marylore Chenel BSA-adjusted dose? An old method to fight old bias
I-43 S. Y. Amy Cheung Structural identifiability of parallel pharmacokinetic experiments as constrained systems
I-52 Emmanuelle Comets A comparison of bootstrap approaches for estimating standard errors of parameters in linear mixed effects models
I-53 Carolyn Coulter Utilising prior literature population models to inform clinical practice - a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdose
I-55 Roosmarijn De Cock Maturation of GFR in preterm and term neonates reflected by clearance of different antibiotics
I-58 Maud Delattre Pharmacokinetics and stochastic differential equations : model and methodology.
I-64 Aris Dokoumetzidis Numerical solution of nonlinear fractional compartmental systems
I-65 Aris Dokoumetzidis Multiple dosing for linear fractional pharmacokinetic systems
II-13 Axel Facius Modelling and Simulation based Techniques to support Trial Design and Submission of Daxas 
II-19 Christina Friedrich Comparison of Statistical and Physiological Modeling Methods Using Examples in Drug Discovery and Development
II-47 Vijay Ivaturi Selection Bias in Pre-Specified Covariate Models
II-53 Åsa Johansson Comparison of methods for handling missing covariate data
II-57 Takayuki Katsube Evaluation of Stepwise Covariate Model Building Combined with Cross-Validation
II-58 Ron Keizer The bootstrap of Stepwise Covariate Modeling using linear approximations
II-62 Akash Khandelwal Influence of Correlated Covariates on Predictive Performance for Different Models
III-11 Natacha Lenuzza Development of a PK library of parent drug/metabolite integrated models
III-18 Eleonora Marostica Population state-space modelling of patient responses in antidepressant studies
III-19 Hafedh Marouani Kinetic nomograms assist individualization of drug regimens
III-23 Christophe Meille PK/PD Model of skin toxicity in animal reported as binary outcome
III-60 Klaas Prins Modeling urge urinary incontinence data acknowledging non-Poisson dispersion of counts within individual provides a major model fit improvement.
III-61 Klaas Prins Use of a generalized poisson model to describe micturition frequency in patients with overactive bladder disease.
IV-1 Alberto Russu Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression
IV-14 Doerthe Steller Extension of Continuous-Time PK/PD Markov Models to Published Count Data
IV-23 Nadia Terranova A non parametric population approach for selecting biomarkers of a drug action
IV-25 Michel Tod A meta-analysis regression model for quantitative prediction of the impact of polymorphism on drug exposure
IV-29 Kuenhi Tsai Evaluating Bootstrap Methods in Nonlinear Mixed Effect Models (NMEM) Using a PK Model
IV-48 Thomas Wendl Modeling of renal failure, dialysis, inhalation and mechanical ventilation: Development of a whole-body physiologically-based pharmacokinetic (PBPK) model for ICU patients with and without renal failure receiving inhalatively administered Amikacin via a t

Posters: Paediatrics

I-1 Leon Aarons Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children
I-4 Hesham Al-Sallami A semi-mechanistic model for estimating lean body weight in children
I-27 Marion Bouillon-Pichault Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4
I-36 Massimo Cella Implementation of Pharmacokinetic Bridging for Drug Combinations in Children
I-38 Pascal Chanu A dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH)
I-48 Karina Claaßen Evaluation of a PBPK Model for Preterm Neonates by Predicting Paracetamol Pharmacokinetics
II-5 Cyrielle Dumont Design optimisation of a pharmacokinetic study in the paediatric development of a drug
II-8 Esther Encinas Fentanyl pharmacokinetic and pharmacodynamic (PK/PD) estimation in neonates and infants using allometric and ontogeny methods
II-12 David Fabre Population Pharmacokinetics of Alfusozin in children and adolescents
II-32 Andreas Velsing Groth Predicting paediatric PK in order to investigate it
II-39 Anna-Karin Hamberg Predictions of warfarin exposure and INR response in children
II-41 Sarapee Hirankarn Population K-PD Model of Sodium Nitroprusside in Neonates and Children During Anesthesia or Sedation.
II-45 Ibrahim Ince Population PK of midazolam from preterm neonates to adults, a maturation model
II-56 Nastya Kassir An Optimal Sampling Strategy for Tacrolimus in Pediatric Liver Transplant Recipients Based on a Population Pharmacokinetic Model
II-63 Sung Eun Kim Population Pharmacokinetics of Theophylline in Premature Korean Infants
II-64 Holly Kimko Disease-Drug Model of Methylphenidate (MPH) in Children with Attention Deficit Hyperactivity Disorder Via Longitudinal Meta-analysis
III-3 Elke Krekels Maturation of glucuronidation; a system specific property
III-20 Amelie Marsot Population pharmacokinetics of Phenobarbital in neonates and infants.
III-45 Parul Patel Dried Blood Spots and Sparse Sampling: A perfect combination for minimally invasive PK/PD studies in children
III-53 Chiara Piana Impact of non-adherence to antiretroviral therapy in HIV-infected children
IV-10 Ivy Song Dose Selection of Dolutegravir (DTG, S/GSK1349572) in Pediatric Studies
IV-31 Wanchana Ungphakorn Population Pharmacokinetics and Use of Monte Carlo Simulation To Determine Optimal Dosing Regimen of Oral Ciprofloxacin in Paediatric Patients with Severe Malnutrition
IV-33 Pyry Välitalo Pharmacokinetics of Oxycodone in Labouring Women With Preliminary Estimates of Neonatal Exposure
IV-39 Sven van Dijkman Optimal design for a dexmedetomidine pharmacokinetic trial in mechanically ventilated neonates with single organ respiratory failure.
IV-44 Katarina Vucicevic Population Pharmacokinetic Modelling of Amikacin in Neonates
IV-46 Chenguang Wang The allometric exponent for maturation in propofol clearance varies with age
IV-64 Wei Zhao Individualized therapy and Bayesian estimator of ganciclovir exposure after oral administration of valganciclovir in pediatric renal transplant patients

Posters: Study design

I-7 Kristoffersson Anders Optimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects.
I-8 Claus Andersen Trial Sample Size Estimation and Study Design Assessment using Monte Carlo Sampling
I-12 Caroline Bazzoli New features for population design evaluation and optimisation with R functions: PFIM Interface 3.1 and PFIM 3.2
I-34 Núria Buil Bruna The feasibility of model-based exposure calculations in preclinical toxicology
II-4 Anne Dubois Evaluation of designs for biosimilarity crossover trials analysed by nonlinear mixed effects models
II-6 Cyrielle Dumont Design evaluation in nonlinear mixed effect models: influence of covariance between random effects
II-30 Gordon Graham An Application of Optimal Design to Dose Selection and Sample Size Determination with a Negative-Binomial Exposure-Response Model for a Phase IIb Study
II-54 Matts Kågedal Improved study design in phase IIb by the use of optimal design, focusing on the precision of dose finding
III-12 Karl-Heinz Liesenfeld Modeling and simulation to optimise the study design investigating the hemodialysis of dabigatran in patients with end stage renal disease (ESRD)
III-24 France Mentré Comparison of results of the different software for design evaluation in population pharmacokinetics and pharmacodynamics
III-32 Thu Thuy Nguyen Evaluation of Fisher information matrix using Gaussian quadrature in nonlinear mixed effects models: application to dose-response trials
III-33 Thu Thuy Nguyen Designing a dose-response study analysed by nonlinear mixed effects models
III-38 Joakim Nyberg Parallelization in optimal experimental design using PopED
III-39 Joakim Nyberg Population optimal design with correlation using Markov Models
III-59 Italo Poggesi Efficiency criteria generated by optimal design tools should be evaluated in the light of study objectives
III-64 Elba Romero PK/PD sampling design optimization following a sustained release formulation of triptorelin using optimal experimental design
IV-20 Amit Taneja Optimisation of Screening Experiments for the Assessment of Analgesic Effects
IV-24 Donato Teutonico Multivariate patient simulation for clinical trial optimization in COPD
IV-43 Camille Vong Optimal Design of Anticancer Regimens
IV-56 Shuying Yang Using Placebo FEV1 Response to Improve the efficiency of clinical trials in Asthma